

Molecular cloning and functional expression of the first insect FMRFamide receptor

Giuseppe Cazzamali and Cornelis J. P. Grimmelikhuijzen*

Department of Cell Biology, Zoological Institute, University of Copenhagen, Universitetsparken 15, DK-2100 Copenhagen, Denmark

Communicated by William S. Bowers, University of Arizona, Tucson, AZ, July 25, 2002 (received for review May 1, 2002)

FMRFamide and FMRFamide-related neuropeptides are extremely widespread and abundant in invertebrates and have numerous important functions. Here, we have cloned a *Drosophila* orphan receptor, and stably expressed it in Chinese hamster ovary cells. Screening of a peptide library revealed that the receptor reacted with high affinity to FMRFamide (EC₅₀, 6 × 10⁻⁹ M). The intrinsic *Drosophila* FMRFamide peptides are known to be synthesized as a large preprohormone, containing at least 13 related FMRFamide peptides (8 distinct FMRFamides). Screening of these intrinsic *Drosophila* FMRFamides showed that the receptor had highest affinity to *Drosophila* FMRFamide-6 (PDNFMRFamide) (EC₅₀, 9 × 10⁻¹⁰ M), whereas it had a somewhat lower affinity to *Drosophila* FMRFamide-2 (DPKQDFMRFamide) (EC₅₀, 3 × 10⁻⁹ M) and considerably less affinity to the other *Drosophila* FMRFamide-related peptides. To our knowledge, this article is the first report on the molecular identification of an invertebrate FMRFamide receptor.

The invertebrate neuropeptide FMRFamide was originally isolated from clam ganglia, because of its prominent cardio-excitatory actions (1). Since then, FMRFamide and FMRFamide-related peptides have been isolated from a wide variety of invertebrate species, ranging from primitive metazoans, such as cnidarians, to higher invertebrates, such as insects (2–5). FMRFamide-related peptides occur in all classes of cnidarians, suggesting that these peptides were among the first transmitters used in evolution (6). After their discovery in invertebrates, FMRFamide-related substances have also been purified from mammals and other vertebrates (7–9), suggesting that these peptides occur in all animals having a nervous system.

The preprohormones of the FMRFamide-related peptides in invertebrates are characterized by a large number of FMRFamide peptide copies, ranging from 38 copies (36 identical peptides) in cnidarians (6, 10), to 29 copies (28 FMRFamides and one FLRFamide copy) in molluscs (11) and 13 (eight different peptides) in insects (12, 13). FMRFamide-related peptides may act excitatory or inhibitory on their target cells (depending on the target cell type) and they are involved in reproduction, feeding, and many other behaviors (3, 5, 14–18). The abundance, complexity, and importance of FMRFamide peptides within an invertebrate species, is illustrated by the fact that the nematode worm *Caenorhabditis elegans* contains at least 20 FMRFamide preprohormone genes, and that the deletion of only one of these genes causes severe behavioral defects (5, 17, 19).

It might be that not all genes coding for FMRFamide-related peptides are evolutionarily related—i.e., that some genes evolved independently of others by coevolution (20). For example, some FMRFamide-related peptides have only the C-terminal sequence RFamide in common with the FMRFamides, and these peptides might represent a separate, evolutionarily unrelated group.

The actions of the FMRFamide-related peptides are mediated by G protein-coupled receptors (21–23), although in snails (24) and mammals (25) FMRFamide peptides also can directly activate ligand-gated ion channels and, thus, act rapidly. A G protein-coupled receptor from the pond snail *Lymnaea stagnalis* was recently described to be activated by the *Lymnaea* cardio-

excitatory peptide (LyCEP), a neuropeptide that has the C-terminal RFamide sequence in common with the FMRFamides (26). This receptor, however, was not activated by “genuine” FMRFamides—i.e., by peptides having the C-terminal sequence FMRFamide—or by FMRFamide itself (26). The invertebrate G protein-coupled FMRFamide receptor, therefore, has remained elusive, so far. Here, we report on the cloning of the FMRFamide receptor from the fruitfly *Drosophila melanogaster*. This G protein-coupled receptor reacts with high affinity to FMRFamide and the intrinsic *Drosophila* FMRFamide-related peptides. This paper, therefore, is the first report on the cloning and characterization of a “genuine” invertebrate FMRFamide receptor.

Materials and Methods

Cloning of the Receptor and Northern Blot Analyses. Primers were constructed based on the proposed exons of the annotated gene, CG2114 (www.flybase.org), and used in PCR with cDNA from *D. melanogaster* third instar larvae (Canton S) as a template. The sense primer was 5'-AGGGCCCAACGGTACGCTACGA-3' (corresponding to nucleotide positions 140–161 of Fig. 1) and the antisense primer was 5'-AGTAAACCACTGGACCAGGC-GAGGGA-3' (corresponding to nucleotide positions 1497–1522 of Fig. 1). The PCR parameters were one cycle of the following step program: 95°C for 3 min, 56°C for 10 s, 72°C for 2 min, then 35 cycles of the following program step: 95°C for 30 s, 56°C for 10 s, 72°C for 2 min, and a final extension step of 72°C for 10 min. pCR4-TOPO (Invitrogen) was used for the cloning and the SMART RACE cDNA kit (CLONTECH) was used for the rapid amplification of cDNA ends (RACE) reactions. The 3'-RACE reactions were made with the sense primer, 5'-GCTCCATATCGAACAACGGCGAT-GGAACTCTGAACCA-3' (corresponding to nucleotide positions 1274–1310 of Fig. 1), followed by the nested sense primer, 5'-ACTGACCCAGGTCTCGGGATCACCCGGTCTGGTCA-3' (corresponding to nucleotide positions 1443–1477 of Fig. 1). All PCR products were cloned into pCR4-TOPO (Invitrogen), using the TOPO TA cloning method (Invitrogen). Northern blots were prepared, using the NorthernMax-Formaldehyde kit (Ambion, Austin, TX) and BrightStar-Plus membranes (Ambion). A cDNA probe (nucleotide positions 1274–2713 of Fig. 1) was labeled using the Strip-EZ DNA kit (Ambion). The *Drosophila* ribosomal protein 49 (RP-49) probe was generated as described in ref. 27.

Cell Culture, Transfection, and Bioluminescence Assay. Chinese hamster ovary (CHO) cells were grown as described (28). To amplify a full-length cDNA coding for the receptor, the following primers were applied: sense primer 5'-GGTACCAAGAT-GAGTGGTACAGCGGTTGCGCGG-3' (corresponding to nucleotide positions 1–24 of Fig. 1) and antisense primer 5'-GATATCTCAGAATCCAGAGGAGACGTGTCCCAG-3' (corresponding to nucleotide positions 1624–1650 of Fig. 1). The

Abbreviations: CHO, Chinese hamster ovary; DFR, *Drosophila* FMRFamide receptor.

Data deposition: The data sets for Fig. 1 have been deposited in the GenBank database (accession no. AF351129).

*To whom reprint requests should be addressed. E-mail: cgrimmelikhuijzen@zi.ku.dk.

ATTCATTCCAATTGATTAACCCCATCGCGCCGACTGTCCCTGGCATTGATTGTGA

CATTCTCGCCGCCAAGATATGCAATGGGAATATGCGAATATCTTGCACACACACTCGTGTGTTAAATTAATTCCTCAAGCTTAAAGTGTGACGGCGC -298
CGGGTGGAGCCAGGACAAAGGACATAGTCATCAGGTGCTCGTGACCCCTGAACCGTGCAACAATAAGTATCCGACCTGTGGCCGAGAATGTATGTTTC -199
GTGCGAAAGTTACCCGTCGGCTGCCTAAATGCTACGTCACGATTTCGATAAGGGTTAGGCTTACGCATCGGGGAAGTGGGTGAGTACTCCGGGAGCC -100
-1

ATG AGT GGT ACA GCG GTT GCG CGG CTC CTG CTC CGC CTG GAG CTA CCC TCG CCA GGC GTA ATG CCA CCA CCG CCC 75
Met Ser Gly Thr Ala Val Ala Arg Leu Leu Leu Arg Leu Glu Leu Pro Ser Pro Gly Val Met Pro Pro Pro Pro 25

ACG GAC TAC GAT TAC GGT GGA CCC ATC AGC GAC GAT GAG TTC CTG GCC AGT GCG ATG GCC ACC GAG GGC CCA ACG 150
Thr Asp Tyr Asp Tyr Gly Gly Pro Ile Ser Asp Asp Glu Phe Leu Ala Ser Ala Met Ala Thr Glu Gly Pro Thr 50

GTA GCG TAC GAT TTG TTT CCG CAG AAC AAC AGT CAG CCC ACT CTG CAA ATC GTC CTT AAC CAC ACG GAG GTG CAA 225
Val Arg Tyr Asp Leu Phe Pro Gln Asn Asn Ser Gln Pro Thr Leu Gln Ile Val Leu Asn His Thr Glu Val Gln 75

ACG GAT CTG CAA TAT CCC CAC TAC GAG GAC CTG GGC CTG GAT CCC GAT CCG AAT TGG ACA CGA ATC TGC GAG GAT 300
Thr Asp Leu Glu Tyr Pro His Tyr Glu Asp Leu Glu Leu Asp Pro Asp Pro Asn Trp Thr Arg Ile Cys Glu Asp 100

TM I

GTG TAC AAC CCA CTG CTG GAG AAC AAT CGC ATT GAG TTC TGG GTG TGC GGA GTA CTG ATA AAT ATC GTT GGT GTC 375
Val Tyr Asn Pro Leu Leu Glu Asn Asn Arg Ile Glu Phe Trp Val Cys Gly Val Leu Ile Asn Ile Val Gly Val 125

CTC GGC ATC CTA GGC AAC ATA ATC TCC ATG ATA ATC CTC TCC CGA CCA CAG ATG AGA TCC AGT ATC AAC TAC TTG 450
Leu Gly Ile Leu Gly Asn Ile Ile Ser Met Ile Ile Leu Ser Arg Pro Gln Met Arg Ser Ser Ile Asn Tyr Leu 150

TM II

CTC ACT GGA TTG GCC CGC TGT GAT ACG GTG CTG ATT ATC ACC TCT ATC CTG CTG TTT GGA ATA CCC AGC ATA TAT 525
Leu Thr Gly Leu Ala Arg Cys Asp Thr Val Leu Ile Ile Thr Ser Ile Leu Leu Phe Gly Ile Pro Ser Ile Tyr 175

CCA TAT ACG GGT CAC TTT TTC GGC TAC TAC AAC TAT GTT TAT CCG TTT ATA TCG CCG GCG GTA TTC CCT ATA GGC 600
Pro Tyr Thr Gly His Phe Phe Gly Tyr Tyr Asn Tyr Val Tyr Pro Phe Ile Ser Pro Ala Val Phe Pro Ile Gly 200

TM III

ATG ATA GCC CAG ACA GCT AGT ATA TAT ATG ACA TTT ACG GTG ACC TTA GAG AGA TAT GTA GCC GTT TGC CAT CCT 675
Met Ile Ala Gln Thr Ala Ser Ile Tyr Met Thr Phe Thr Val Thr Leu Glu Arg Tyr Val Ala Val Cys His Pro 225

TM IV

CTG AAG GCG AGA GCA CTC TGC ACT TAC GGA AGA GCT AAA ATA TAT TTC ATA GTT TGT GTA TGC TTC TCG TTG GCC 750
Leu Lys Ala Arg Ala Leu Cys Thr Tyr Gly Arg Ala Lys Ile Tyr Phe Ile Val Cys Val Cys Phe Ser Leu Ala 250

TAC AAT ATG CCC AGA TTT TGG GAG GTC CTG ACT GTC ACC TAT CCC GAA CCG GGC AAG GAT GTA ATA CTC CAC TGC 825
Tyr Asn Met Pro Arg Phe Trp Glu Val Leu Thr Val Thr Tyr Pro Glu Pro Gly Lys Asp Val Ile Leu His Cys 275

GTG AGA CCT TCG AGA CTG AGA AGA TCG GAG ACC TAC ATC AAC ATA TAC ATA CAC TGG TGC TAC CTG ATA GTG AAC 900
Val Arg Pro Ser Thr Arg Arg Ser Glu Thr Tyr Ile Asn Ile Tyr Ile His Trp Cys Tyr Leu Ile Val Asn 300

TM V

TAT ATC ATA CCC TTT CTC ACC CTA GCC ATA CTA AAT TGT CTG ATA TAC AGG CAG GTG AAG AGG GCT AAT AGG GAG 975
Tyr Ile Ile Pro Phe Leu Thr Leu Ala Ile Leu Asn Cys Leu Ile Tyr Arg Gln Val Lys Arg Ala Asn Arg Glu 325

TM VI

CGC CAG AGG TTA TCG AGA TCA GAG AAA AGG GAG ATC GGA TTG GCC ACA ATG CTG CTG TGC GTG GTA ATG TTC 1050
Arg Gln Arg Leu Ser Arg Ser Glu Lys Arg Glu Ile Gly Leu Ala Thr Met Leu Leu Cys Val Val Ile Val Phe 350

TTT ATG CTC AAC TTT CTA CCG CTG GTG CTC AAT ATA TCC GAG GCC TTC TAT AGC ACC ATC GAT CAT AAA ATT ACG 1125
Phe Met Leu Asn Phe Leu Pro Leu Val Leu Asn Ile Ser Glu Ala Phe Tyr Ser Thr Ile Asp His Lys Ile Thr 375

TM VII

AAG ATC TCC AAT CTA CTG ATC ACC ATC AAT AGC AGT GTC AAC TTT CTC ATT TAC ATC ATC TTC GGC GAA AAG TTC 1200
Lys Ile Ser Asn Leu Leu Ile Thr Ile Asn Ser Ser Val Asn Phe Leu Ile Tyr Ile Ile Phe Gly Glu Lys Phe 400

AAG CGC ATT TTT TTA CTC ATT TTT TTC AAG CGC CGC CTG AGT CGT GAC CAA CCG GAT CTT ATC CAC TAC GAG AGC 1275
Lys Arg Ile Phe Leu Leu Ile Phe Phe Lys Arg Arg Leu Ser Arg Asp Gln Pro Asp Leu Ile His Tyr Glu Ser 425

TCC ATA TCG AAC AAC GGC GAT GGA ACT CTG AAC CAC CGA TCC TCC GGC CGC TTC TCG AGG CAC GGC ACC CAG CGG 1350
Ser Ile Ser Asn Asn Gly Asp Gly Thr Leu Asn His Arg Ser Ser Gly Arg Phe Ser Arg His Gly Thr Gln Arg 450

AGC ACC ACC ACC ACC TAC CTG GTG GCC ACC GGA GGA CCA GGC GGT GGG GGA TGC GGT GGT GGC GGT GGC AAT AAT 1425
Ser Thr Thr Thr Thr Tyr Leu Val Ala Thr Gly Gly Pro Gly Gly Gly Gly Cys Gly Gly Gly Gly Gly Asn Asn 475

TCC CTC AAT AAT GTC CGA CTG ACC CAG GTC TCG GGA TCA CCC GGT CTG GTC AAG ATC AAG CGA AAT CGA GCT CCC 1500
Ser Leu Asn Asn Val Arg Leu Thr Gln Val Ser Gly Ser Pro Gly Leu Val Lys Ile Lys Arg Asn Arg Ala Pro 500

TCG CCT GGT CCA GTG GTT TAC TTT CCC GCC CGC GAA ATG CAG AGA TCC GCA TCC ACA ACA AAT TCA ACA ACC AAT 1575
Ser Pro Gly Pro Val Val Tyr Phe Pro Ala Arg Glu Met Gln Arg Ser Ala Ser Thr Thr Asn Ser Thr Thr Asn 525

AAC AAC ACT TCT ATT GGT TAC GAC TGG ACC CTG CCG GAC AGC AAA AAA CTG GGA CAC GTC TCC TCT GGA TTC TGA 1650
Asn Asn Thr Ser Ile Gly Tyr Asp Trp Thr Leu Pro Asp Ser Lys Lys Leu Gly His Val Ser Ser Gly Phe ★ 549

GATTGTGTCGGGCAAAAACGATTAGAAGGGTTACATGGAAGGGTTGACTTAGAGCACCAATCTTGTAAATAGGATAGACACGGAAATAGGGCTTAA 1749
CAACACAGCTGTGGTCAAAAATAGTAGTAGCATTTCTTTACATTTCTTTAAACATTTGGAATTTTAAAGGAGATTTAATTTCCAATCTGAATAATATATTATA 1848
AAAAAACTAATCACTTTAAATAATTTGATGAATTCACGAGTTTAAATAATCAAACTATAATGAAATCTAAAAAAACGATGAATGCGATTTTGGG 1947
TAAATAATTTATCGATTATTAAGGTGAACGTAGCTTTTAAATTTAATAAAAACATTTTCTAAGTGGCATGAGTGCCCGGGAATGCTAATTTTTCAC 2046
CGGAGGTGTAACACTACTAAGTACTACTATAGTTTGTACAGAAGGCATAAACTATGCGCTCCAAGCGTTGAGTTACTTGTGATAAGCGTAAATGTTTCCT 2145
TCCCAATTTCTCTACTACTCCCTCCAGAACTTAACCTCGTTGATATAGATTTAAGAAAGTTAGTTTCAGTGGCGCCAGGCTGAAGAAAATAGTTTCTT 2244
AGACTGAGAGTTTAAATATTTGTTTTCCTAACGTTTTCCTATCATTTCCTCCGGTTCAATGAATTTGATCAATTTTCGCACATAAATAGTCATCGA 2343
AATTTTCCGAACCCAAATATCGTTTCTACTTCTACTGGCCTTTGTCGGAAGTTTATTTATAGCGTAAACTTTAGCTGCCCTAATTAATAATCCCTTT 2442
ACGACGATTTTCTCGGCCGAACCTTGATGAATGATTTTCTTTTCTTTGGCTGATTTGGGTTTCCCGAACTTTTCGATTTCCCTCACACTTTACCGGAAA 2541
CTGGGGTTCTTCGGGTCAAAATATACAAGGCCGGGCAATCTGTCAACTTGTCAAGAAAGTTTAAATGCCCGCTCAAAGTTTCAGTCAGCTCAAAAGTT 2640
TGCCAGCATTTATTAGTCGCCCTAAAACCTCAAGTAGCTCAATTTAACAGCAAAATGCAACAATAATAACAAC (A)_n 2713

Fig. 1. cDNA and deduced amino acid sequence of the *Drosophila* receptor CG2114. Nucleotides are numbered from 5' to 3' end and the amino acid residues are numbered starting with the first ATG codon in the ORF. The two nucleotides bordering the single intron found to be present in the gene are highlighted in gray. The seven membrane spanning domains are boxed and labeled TM I–VII. The translation termination codon is indicated by an asterisk. In-frame stop codons in the 5'-noncoding region are underlined. The putative polyadenylation signal in the 3'-noncoding region is underlined twice. Putative glycosylation sites in the extracellular N terminus and in the third extracellular loop, following the N-X-S/N-X-T consensus sequence, are indicated by a triangle.

Table 1. Intron/exon boundaries of *D. melanogaster* gene CG2114

Intron	5' donor	Intron size, bp	3' acceptor
1	AAG gtaagca. . .	6246	. . .tttcag CTT

product was cloned into pCR4-TOPO vector (Invitrogen). Several independent clones were sequenced to verify the correct amplification of the cDNA. The *KpnI* and *EcoRV* restriction sites that had been incorporated into the above primers facilitated the subcloning into pCDNA3.1 (Invitrogen). cDNA from third instar *D. melanogaster* larvae was used as a template. The same transfection method was used as described earlier (28). The bioluminescence assay is described in refs. 28 and 29.

Sequence Analysis. DNA sequence compilation, and nucleotide and amino acid sequence comparisons were performed using the LASERGENE DNA software package (DNASTar, Madison, WI). The secondary structure of the receptor protein was analyzed using the TMHMM V.2.0 prediction server from the Center for Biological Sequence Analysis, Danish Technical University (www.cbs.dtu.dk).

Peptides. The peptides used in this paper were either custom synthesized by Genemed Synthesis, San Francisco (*D. melanogaster* FMRFamides 1–8; drostatins-A4, -B2, -C; *D. melanogaster* myosuppressin; *D. melanogaster* short neuropeptide F1; *D. melanogaster* tachykinin-3; and *D. melanogaster* adipokinetic hormone), or purchased from Bachem, Bubendorf, Switzerland (FMRFamide, *D. melanogaster* crustacean cardioactive peptide, cockroach perisulfakinin, cockroach leucokinin III, and cockroach leucopyrokinin).

Results

We and others have previously cloned and functionally characterized two *Drosophila* allatostatin receptors (30–34). To find additional *Drosophila* allatostatin receptors, we used the BLAST algorithm to screen the *Drosophila* Genome Project database

(www.flybase.org) and found among the highest scores the sequence of gene CG2114, which was annotated to be a G protein-coupled receptor. We subsequently designed primers against the proposed exons of this receptor gene and performed PCR, using cDNA of larval *D. melanogaster* as a template. This PCR yielded a band of the expected size and sequence, and after 3'- and 5'-RACE, we obtained the full-length sequence of the receptor cDNA (Fig. 1).

The cDNA of Fig. 1 is 3,061 nucleotides long. It has a 5'-untranslated region of 356 nucleotides, which contains various stop codons, and a long 3'-untranslated region of 1,063 nucleotides, containing a polyadenylation signal. The cDNA sequence codes for a protein of 549 amino acid residues, which contains seven transmembrane domains. The extracellular N terminus has three potential N-glycosylation sites, whereas the third extracellular loop contains one (Fig. 1).

Comparison of the cDNA with the genomic sequence of the annotated gene CG2114 (www.flybase.org) revealed the presence of one intron located within the 5'-untranslated region (Fig. 1, Table 1). This alignment also showed that the genomic organization of the gene had been correctly predicted. Furthermore, no nucleotide differences existed between the annotated exons and our cloned cDNA (Fig. 1). The gene CG2114 maps in chromosome 3L, position 63 B2. There are no existing mutations available in the gene (www.flybase.org).

Comparison of the amino acid sequence of the receptor with that of other proteins from the GenBank database showed that the receptor has a remarkably high sequence identity with a recently released *Anopheles gambiae* gene product, agCP12601 (53% amino acid residue identity, 68% conserved residues; Fig. 2). Only a much lower amount of sequence identity exists with the *Drosophila* allatostatin receptors DAR-1 and -2 (23%), the *Drosophila* neuropeptide Y receptor (24%), the *Drosophila* tachykinin receptors (23%), the mouse TSH-releasing-hormone receptor (24%), and the rat kappa opioid receptor-1 (24%). All other proteins from the database showed less structural resemblance with the receptor.

A Northern blot of the various developmental stages of *Drosophila* showed that the *Drosophila* receptor was expressed in all stages, but mainly in larvae and adult flies (Fig. 3). The size

BIOCHEMISTRY



Fig. 2. Amino acid sequence comparison between the *Drosophila* FMRFamide receptor (DFR) from Fig. 1 and the annotated *Anopheles* protein, agCP12601 (the putative protein encoded by the annotated gene agCG53608), which shows the highest score during a BLAST search of the GenBank database. Amino acid residues that are identical between DFR and agCP12601 are highlighted in gray. The seven membrane spanning domains are indicated by TM I–VII.




Fig. 3. Northern blots of mRNA isolated from the various developmental stages of *Drosophila*. The sizes of the transcripts are given at the right (in kb). (A) Each lane contained 5 μ g of mRNA from embryos (0–24 h), larvae (1st, 2nd, and 3rd instar), pupae, and adult flies (mixed male and female), which was hybridized with a cDNA probe, coding for a part of the *Drosophila* receptor (corresponding to nucleotide positions 1274–2713 of Fig. 1). (B) The Northern blot from A was stripped and subsequently incubated with a cDNA probe, coding for RP-49. This blot gives the loading efficiency in each lane.

of the transcript (3.2 kb) corresponded well with that of the cloned cDNA (Fig. 1).

We stably expressed the receptor in CHO cells that also stably expressed the promiscuous G protein, G₁₆ (29). Two days before the assay (see below), we transiently transfected these cells with DNA, coding for apoaequorin, and 3 h before the assay we added coelenterazine to the cell medium. Activation of the receptor in these pretreated cells would result in a Ca²⁺-induced bioluminescence response that could easily be measured and quantified (28, 29, 33, 35).

We applied the “reverse pharmacology” strategy (36) during our attempts to find the endogenous ligand for the receptor—i.e., we tested a peptide library of *Drosophila* and other insect or invertebrate peptide hormones. Addition of 10^{−5} or 10^{−6} M of these peptides to the pretreated CHO cells gave negative results for many of these peptides, but peptides resembling FMRFamide at their C termini, and FMRFamide itself, gave clear bioluminescence responses (Fig. 4A–F). Because FMRFamide was the most potent peptide in inducing the bioluminescence response (Fig. 4F), we synthesized all eight *Drosophila* FMRFamide-related peptides that are known to be contained in the *Drosophila* FMRFamide preprohormone (12, 13). After testing these peptides in our bioluminescence assay, we found that *Drosophila* FMRFamide-6 (PDNFMRFamide) was the most potent intrinsic *Drosophila* peptide (EC₅₀, 9 × 10^{−10} M), whereas the other peptides were less effective (Fig. 4G). *Drosophila* FMRFamide-4 (SDNFMRFamide), for example, showed only a very low efficacy (EC₅₀, > 5 × 10^{−7} M), whereas *Drosophila* FMRFamide-7 (SAPQDFVRSamide) showed no activity at all.

Discussion

From invertebrates, only one receptor for an FMRFamide-related peptide has been cloned so far, which is the receptor for the *L. stagnalis* cardioexcitatory peptide (LyCEP) (TPH-WRPQGRF-NH₂; ref. 26). LyCEP, however, has only the last two amino acid residues (RFamide) in common with FMRFamide and might, therefore, not be a “genuine” FMRFamide peptide. This conclusion is supported by the finding that the LyCEP receptor does not react with FMRFamide itself (26), a neuropeptide that is present in *L. stagnalis* and probably all other

molluscs (1, 18). Our cloning of a “genuine” FMRFamide receptor from *Drosophila* (Figs. 1 and 4), therefore, is the first report on the cloning of an invertebrate FMRFamide receptor.

Dose–response curves for the intrinsic *Drosophila* FMRFamide-related peptides showed that the *Drosophila* peptide FMRFamide-6 (PDNFMRFamide) has the highest potency to activate the receptor (EC₅₀, 9 × 10^{−10} M; Fig. 4G), whereas the other *Drosophila* FMRFamides are clearly less active: *Drosophila* FMRFamide-2 (DPKQDFMRFamide) by a factor of 3; *Drosophila* FMRFamides-3 (TPAEDFMRFamide), -5 (SPKQDFMRFamide), and -8 (MDSNFIRFamide) by a factor of 8; and *Drosophila* FMRFamide-1 (SVQDNFMHFamide) by a factor of 42 (Fig. 4G). In addition, two other peptides showed only a very low affinity for the receptor: *Drosophila* FMRFamide-4 (SDNFMRFamide) needed more than thousand times higher concentrations to give the same response as *Drosophila* FMRFamide-6, whereas *Drosophila* FMRFamide-7 (SAPQDFVRSamide) did not react at all (Fig. 4G). These results indicate that the new *Drosophila* receptor is the intrinsic receptor for *Drosophila* FMRFamide-6, but that it cannot be the physiologically relevant receptor for all eight *Drosophila* FMRFamides that are known to be contained within the *Drosophila* FMRFamide preprohormone (12, 13). *Drosophila* FMRFamide-2, however, is present with five copies in the *Drosophila* FMRFamide precursor (12, 13). Thus, it could be expected that the concentration of *Drosophila* FMRFamide-2 in the hemolymph or synapses is about five times higher than that of *Drosophila* FMRFamide-6, which would compensate for the somewhat lower affinity of the *Drosophila* FMRFamide-2 peptide for the receptor. Under *in vivo* conditions, therefore, the new receptor could be the cognate receptor for both FMRFamide-6 and -2. The situation for *Drosophila* FMRFamide-3 and -5, however, is unclear. If all *Drosophila* FMRFamides are released simultaneously and their concentrations are in accordance to their stoichiometry in the preprohormone, then the receptor would already be fully activated by FMRFamide-6 (and -2), before the FMRFamides-3 and -5 start to be active (around 10^{−9} M; Fig. 4G). Therefore, if no differential processing of the preprohormone, or alternative splicing of its gene transcript occurs (ref. 37; see, however, ref. 38), the new receptor would not be the cognate receptor for FMRFamides-3 and -5. The same holds for FMRFamide-1. Furthermore, the novel receptor is clearly not the cognate receptor for *Drosophila* FMRFamide-4 and -7 (Fig. 4G).

The above arguments, therefore, suggest that *Drosophila* has additional FMRFamide receptors. One would expect that these additional receptors are structurally related to the one cloned in this paper (Fig. 1). Screening of the *Drosophila* Genome Project database, using the BLAST algorithm, however, did not yield additional G protein-coupled receptors that were closely related to the one from Fig. 1. The additional FMRFamide receptors from *Drosophila*, therefore, might have amino acid residue identities of below 23% with the first *Drosophila* FMRFamide receptor, which would make them difficult to be recognized as FMRFamide receptors.

We have found that the *Drosophila* FMRFamide receptor can also be activated by peptides that are not “genuine” FMRFamides, such as *Drosophila* short neuropeptide F-1 (AQRSPSLRLRFamide; ref. 39) and *Drosophila* myosuppressin (TDVDH-VFLRFamide; ref. 39). These peptides, however, can only activate the receptor at concentrations above 10^{−8} M (Fig. 4F), and again, are not likely to be ligands under normal physiological conditions.

From the dose–response curves of Fig. 4G, it is clear that the receptor recognizes more amino acid residues than the C-terminal FMRFamide sequence and, therefore, is able to discriminate between the various intrinsic *Drosophila* peptides. For two peptides, this discrimination is extreme: FMRFamide-6 (PDNFMRFamide) is recognized very well, whereas




Fig. 4. Bioluminescence response of a CHO/G₁₆ cell line transfected with cDNA coding for the receptor shown in Fig. 1 (CHO/G₁₆/DFR); and of a nontransfected cell line (CHO/G₁₆). The vertical bars represent SEM, which are sometimes lower than the symbols (circles, squares, triangles, etc.) used. In these cases, only the symbols are given. (A) Bioluminescence response of CHO/G₁₆/DFR after addition of 5×10^{-8} M of Drm-FMRFamide-6. (B) Response of CHO/G₁₆ cells after addition of 5×10^{-8} M Drm-FMRFamide-6. (C) Response of CHO/G₁₆/DFR cells after addition of PBS alone. (D) Response of CHO/G₁₆/DFR cells after addition of 5×10^{-8} M FMRFamide. (E) Response of CHO/G₁₆/DFR cells after addition of 5×10^{-8} M *Drosophila* myosuppressin (Drm-MS). (F) Dose-response curves of the bioluminescence responses of CHO/G₁₆/DFR cells induced by various *Drosophila* or other invertebrate peptides: FMRFamide (1), *Drosophila* short neuropeptide F1 (Drm-sNPF1; ref. 39), Drm-MS (39), *Drosophila* adipokinetic hormone (Drm-AKH; refs. 28 and 43), *Drosophila* crustacean cardioactive peptide (Drm-CCAP; ref. 39), *Drosophila* tachykinin-3 (Drm-TK-3; ref. 44), drostatin-A4 (45), drostatin-B2 (46), drostatin-C (47), cockroach perisulfakinin (48), cockroach leucokinin III (49), and cockroach leucopyrokinin (49). Of all peptides tested, only FMRFamide, Drm-sNPF1, Drm-MS, and (at only very high concentrations) perisulfakinin induce bioluminescence. (G) Dose-response curves of the bioluminescence responses of CHO/G₁₆/DFR cells induced by the peptides that are contained in the *Drosophila* FMRFamide preprohormone (12, 13). *Drosophila* FMRFamide-6 is the most potent peptide (EC₅₀, 9×10^{-10} M). (H) Amino acid sequences of the FMRFamide-related peptides contained in the *Drosophila* FMRFamide preprohormone. FMRFamide-2 is present with five copies, FMRFamide-3 is present with two copies in the preprohormone. The common C-terminal FMRFamide moieties are highlighted. DFR, *Drosophila* FMRFamide receptor; Drm-AKH, *Drosophila* adipokinetic hormone; Drm-CCAP, *Drosophila* crustacean cardioactive peptide; Drm-MS, *Drosophila* myosuppressin; Drm-sNPF1, *Drosophila* short neuropeptide F1; Drm-TK-3, *Drosophila* tachykinin-3; G₁₆, G protein-16.

FMRFamide-4 (SDNFMRFamide), where the first amino acid residue proline has been exchanged for a serine residue, is only very poorly recognized. Furthermore, the C-terminal sequence FMRFamide alone is much more effective than, for example, *Drosophila* FMRFamide-4, but much less effective than *Drosophila* FMRFamide-6, which both are peptides containing the C-terminal FMRFamide moiety. These findings suggest that some N-terminal extensions of FMRFamide hamper the activation of the receptor, whereas others have the opposite effect.

The *Drosophila* FMRFamides have been reported to activate larval neuromuscular junctions and to inhibit heartbeat (3, 38,

40, 41). At the larval neuromuscular junctions, all FMRFamides acted similarly (except for FMRFamide-7, which was inactive), suggesting that these peptides were functionally redundant (3, 40). At the heart, however, only FMRFamide-4 was active, whereas FMRFamide-2 and -3 were without effects (38, 41). A comparison of these peptide effects with the characteristics of our FMRFamide receptor (Fig. 4G) makes clear that this receptor cannot be responsible for the actions on the neuromuscular synapses and heart. This finding, again, suggests the existence of multiple *Drosophila* FMRFamide receptors.

In conclusion, we have cloned the first insect FMRFamide receptor. This receptor is a “genuine” FMRFamide receptor and is, therefore, also the first invertebrate FMRFamide receptor to be identified. The sequence of the *Drosophila* FMRFamide receptor might provide the basis for the cloning of many other invertebrate FMRFamide receptors. The *Anopheles* gene product agCP12609 (Fig. 2), for example, might also be an FMRFamide receptor. These findings will lead to a much better understanding of the heterogeneity and actions of invertebrate FMRFamides and, thereby, to an important advancement of invertebrate neuroendocrinology. Furthermore, the availability of a cloned and functionally expressed insect FMRFamide receptor (Fig. 4) may also lead to the development of a new selective and environmentally safe nonpeptide insecticide for use in agriculture or medicine (42). The putative FMRFamide receptor in *Anopheles* (Fig. 2), for example, is a new and

potentially important drug target that might help us to combat malaria. Finally, the possible discovery of an FMRFamide receptor in nematodes will supply us with an essential drug target to fight parasitic nematodes, such as *Brugia malayi*, that causes lymphatic filariasis (also known as elephantiasis), which is the second leading cause of permanent disability worldwide (130 million people infected; 1.1 billion people, 20% of the world’s population, are at risk of infection). All these examples illustrate that our work might also result in useful societal benefits.

We thank Drs. S. Rees and J. Stables (Glaxo Wellcome, Stevenage, U.K.) for supplying cell line CHO/G₁₆, L. Steffensen for typing the manuscript, M. Williamson for critically reading the manuscript, and the Lundbeck Foundation, the Danish Natural Science Research Council (equipment grant), the Carlsberg Foundation (equipment grant), and the Novo Nordisk Foundation for financial support.

- Price, D. A. & Greenberg, M. (1977) *Science* **197**, 670–671.
- Grimmelikhuijzen, C. J. P. & Graff, D. (1986) *Proc. Natl. Acad. Sci. USA* **83**, 9817–9821.
- Taghert, P. H. (1999) *Microsc. Res. Tech.* **45**, 80–95.
- Geary, T. G., Marks, N. J., Maule, A. G., Bowman, J. W., Alexander-Bowman, S. J., Day, T. A., Larsen, M. J., Kubiak, T. M., Davis, J. P. & Thompson, D. P. (1999) *Ann. N.Y. Acad. Sci.* **897**, 212–227.
- Li, C., Kim, K. & Nelson, L. S. (1999) *Brain Res.* **848**, 26–34.
- Grimmelikhuijzen, C. J. P., Leviev, I. & Carstensen, K. (1996) *Int. Rev. Cytol.* **167**, 37–89.
- Yang, H. Y., Fratta, W., Majane, E. A. & Costa, E. (1985) *Proc. Natl. Acad. Sci. USA* **82**, 7757–7761.
- Hinuma, S., Habata, Y., Fujii, R., Kawamata, Y., Hosoya, M., Fukusumi, S., Kitada, C., Masuo, Y., Asano, T., Matsumoto, H., et al. (1998) *Nature (London)* **393**, 272–276.
- Hinuma, S., Shintani, Y., Fukusumi, S., Lijima, N., Matsumoto, Y., Hosoya, M., Fujii, R., Watanabe, T., Kikuchi, K., Terao, Y., et al. (2000) *Nat. Cell Biol.* **2**, 703–708.
- Reinscheid, R. K. & Grimmelikhuijzen, C. J. P. (1994) *J. Neurochem.* **62**, 1214–1222.
- Taussig, R. & Scheller, R. H. (1986) *DNA* **5**, 453–461.
- Schneider, L. E. & Taghert, P. H. (1988) *Proc. Natl. Acad. Sci. USA* **85**, 1993–1997.
- Nambu, J. R., Murphy-Erdosh, C., Andrew, P. C., Feistner, G. J. & Scheller, R. H. (1988) *Neuron* **1**, 55–61.
- Cottrell, G. A. (1993) *Experientia* **63**, 279–285.
- Van Golen, F. A., Li, K. W., de Lange, R. P., Jespersen, S. & Geraerts, W. P. M. (1995) *J. Biol. Chem.* **270**, 28487–28493.
- Scott, M. L., Brezina, V. & Weiss, K. R. (1997) *J. Neurophysiol.* **78**, 2372–2387.
- Li, C., Nelson, L. S., Kim, K., Nathoo, A. & Hart, A. C. (1999) *Ann. N.Y. Acad. Sci.* **897**, 239–252.
- Santama, N. & Benjamin, P. R. (2000) *Microsc. Res. Tech.* **49**, 547–556.
- Nelson, L. S., Rosoff, M. L. & Li, C. (1998) *Science* **281**, 1686–1690.
- Greenberg, M. J. & Price, D. A. (1992) *Prog. Brain Res.* **92**, 25–37.
- Van Tol-Steye, H., Lodder, J. C., Mansvelter, H. D., Planta, R. J., van Heerikhuisen, H. & Kits, K. S. (1999) *J. Neurosci.* **19**, 3739–3751.
- Chiba, O., Sasaki, K., Higuchi, H. & Takashima, K. (1992) *Neurosci. Res.* **15**, 255–264.
- Volterra, A. & Siegelbaum, S. A. (1988) *Proc. Natl. Acad. Sci. USA* **85**, 7810–7814.
- Cottrell, G. A. (1997) *J. Exp. Biol.* **200**, 2377–2386.
- Lingueglia, E., Champigny, G., Lazdunski, M. & Barbry, P. (1995) *Nature (London)* **378**, 730–733.
- Tensen, C. P., Cox, K. J. A., Smit, A. B., van der Schors, R. C., Meyerhof, W., Richter, D., Planta, R. J., Hermann, P. M., van Minnen, J., Geraerts, W. P. M., et al. (1998) *J. Neurosci.* **18**, 9812–9821.
- Hauser, F., Nothacker, H.-P. & Grimmelikhuijzen, C. J. P. (1997) *J. Biol. Chem.* **272**, 1002–1010.
- Staubli, F., Jørgensen, T. J. D., Cazzamali, G., Williamson, M., Lenz, C., Søndergaard, L., Roepstorff, P. & Grimmelikhuijzen, C. J. P. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 3446–3451.
- Stables, J., Green, A., Marshall, F., Fraser, N., Knight, E., Sautel, M., Milligan, G., Lee, M. & Rees, S. (1997) *Anal. Biochem.* **252**, 115–126.
- Birgöl, N., Weise, C., Kreienkamp, H.-J. & Richter, D. (1999) *EMBO J.* **18**, 5892–5900.
- Lenz, C., Søndergaard, L. & Grimmelikhuijzen, C. J. P. (2000) *Biochem. Biophys. Res. Commun.* **269**, 91–96.
- Lenz, C., Williamson, M. & Grimmelikhuijzen, C. J. P. (2000) *Biochem. Biophys. Res. Commun.* **273**, 571–577.
- Lenz, C., Williamson, M., Hansen, G. N. & Grimmelikhuijzen, C. J. P. (2001) *Biochem. Biophys. Res. Commun.* **286**, 1117–1122.
- Larsen, M. J., Burton, K. J., Zantello, M. R., Smith, V. G., Lowery, D. L. & Kubiak, T. M. (2001) *Biochem. Biophys. Res. Commun.* **286**, 895–901.
- Secher, T., Lenz, C., Cazzamali, G., Sørensen, G., Williamson, M., Hansen, G. N., Svane, P. & Grimmelikhuijzen, C. J. P. (2001) *J. Biol. Chem.* **276**, 47052–47060.
- Civelli, O., Nothacker, H. P., Saito, Y., Wang, Z., Lin, S. H. & Reinscheid, R. K. (2001) *Trends Neurosci.* **24**, 230–237.
- Schneider, L. E. & Taghert, P. H. (1990) *J. Biol. Chem.* **265**, 6890–6895.
- Merte, J. & Nichols, R. (2002) *Peptides* **23**, 209–220.
- Vanden Broeck, J. (2001) *Peptides* **22**, 241–254.
- Hewes, R. S., Snowdeal, E. C., III, Saitou, M. & Taghert, P. H. (1998) *J. Neurosci.* **18**, 7138–7151.
- Nichols, R., McCormick, J., Cohen, M., Howe, E., Jean, C., Pasley, K. & Rosario, C. (1999) *J. Neurogenet.* **13**, 89–104.
- Lange, A. B., Orchard, I., Wang, Z. & Nachman, R. J. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 9250–9253.
- Schaffer, M. H., Noyes, B. E., Slaughter, C. A., Thorne, G. C. & Gaskell, S. J. (1990) *Biochem. J.* **269**, 315–320.
- Siviter, R. J., Coast, G. M., Winther, E. M. E., Nachman, R. J., Taylor, C. A. M., Shirras, A. D., Coates, D., Isaac, R. & Nässel, D. R. (2000) *J. Biol. Chem.* **275**, 23273–23280.
- Lenz, C., Williamson, M. & Grimmelikhuijzen, C. J. P. (2000) *Biochem. Biophys. Res. Commun.* **273**, 1126–1131.
- Williamson, M., Lenz, C., Winther, Å. M. E., Nässel, D. R. & Grimmelikhuijzen, C. J. P. (2001) *Biochem. Biophys. Res. Commun.* **281**, 544–550.
- Williamson, M., Lenz, C., Winther, Å. M. E., Nässel, D. R. & Grimmelikhuijzen, C. J. P. (2001) *Biochem. Biophys. Res. Commun.* **282**, 124–130.
- Veenstra, J. A. (1989) *Neuropeptides* **14**, 145–149.
- Gäde, G., Hoffmann, K. H. & Spring, J. H. (1997) *Physiol. Rev.* **77**, 963–1032.